Gilead Sciences, INC Form 4 insider transactions

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, sold 2,500 shares of common stock at a price of $106.4 per share on April 15, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, executed a sale of 2,500 shares of common stock at a price of $110.53 per share, according to a Form 4 filing with the SEC.

Chief Commercial Officer Johanna Mercier reports the vesting of restricted stock units and acquisition of stock options in Gilead Sciences.

Gilead Sciences CEO Daniel O'Day reports the vesting and disposal of restricted stock units and the acquisition of stock options.

EVP Deborah H. Telman reports stock transactions including the vesting of restricted stock units and stock options, as well as adjustments for employee stock purchase plan acquisitions.

Andrew Dickinson, CFO of Gilead Sciences, reports transactions involving company stock, including the exercise of options and sale of shares, pursuant to a pre-arranged trading plan.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the vesting and disposal of restricted stock units and shares acquired through the employee stock purchase plan.

Dietmar Berger, Chief Medical Officer of Gilead Sciences, reports the acquisition of restricted stock units and non-qualified stock options.

Gilead Sciences, Inc. reports acquiring 1,363,636 shares of Arcus Biosciences, Inc. at $11 per share, increasing its holdings to 31,424,760 shares.

Gilead Sciences' CFO, Andrew Dickinson, sold 2,500 shares of common stock at a price of $104.09 per share on February 18, 2025, according to a Form 4 filing with the SEC.

Andrew Dickinson, CFO of Gilead Sciences, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the acquisition of 709 shares of common stock due to performance share award vesting.

EVP Deborah H. Telman reports acquisition of 12,371 shares of Gilead Sciences common stock following performance goal attainment.

Gilead Sciences CEO Daniel O'Day reports acquisition and disposal of company stock related to performance share awards.

Chief Commercial Officer Johanna Mercier reports vesting of performance share awards and subsequent disposal of shares to cover tax obligations.

Andrew Dickinson, CFO of Gilead Sciences, reports the acquisition and disposal of company stock related to performance share awards.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, executed stock options and sold a portion of the acquired shares on January 31, 2025, under a pre-arranged trading plan.

Deborah H. Telman, EVP at Gilead Sciences, reported the acquisition of 515 common stock units and the disposal of 187 common stock units on January 25, 2025.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 2,500 shares of common stock at $91.35 per share on January 15, 2025, under a pre-arranged 10b5-1 trading plan.

Dietmar Berger, Chief Medical Officer of Gilead Sciences, acquired 48,975 restricted stock units on January 2, 2025, according to a recent SEC filing.

Gilead Sciences, Inc. has acquired 940,499 shares of Assembly Biosciences, Inc. at a price of $21.37 per share, increasing its total holdings to 2,209,471 shares.

Gilead Sciences acquired additional common stock and prefunded warrants in Xilio Therapeutics, increasing its beneficial ownership.

Gilead Sciences' Chief Financial Officer, Andrew D. Dickinson, sold 8,500 shares of common stock at $91.96 per share, according to a recent SEC filing.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reported the acquisition and disposal of company stock and restricted stock units on December 13, 2023 and December 13, 2024.

Gilead Sciences executive Deborah H. Telman reports the acquisition of common stock and restricted stock units.

Gilead Sciences' SVP, Controllership, Sandra Patterson, reports the acquisition of common stock and restricted stock units.

Gilead Sciences' Chief Medical Officer, Merdad Parsey, received common stock and restricted stock units on December 10, 2024.

Gilead Sciences CEO, Daniel P. O'Day, exercised stock options and sold a portion of the acquired shares on December 10, 2024.

Johanna Mercier, Chief Commercial Officer at Gilead Sciences, reported the acquisition of 3,752 shares of common stock through the vesting of restricted stock units and the disposition of 1,739 shares to cover tax obligations.

Gilead Sciences' Chief Financial Officer, Andrew Dickinson, received stock and restricted stock units on December 10, 2024, as part of his compensation.